Recommended Version (Default)
Regulatory Update — May 2026
The FDA has proposed excluding semaglutide and liraglutide from the 503B bulk compounding list, with public comments open through June 29, 2026. If finalized, this could affect the availability, pricing, and continuity of some compounded GLP-1 programs. We will update this page as the regulatory situation develops.
The FDA has proposed excluding semaglutide and liraglutide from the 503B bulk compounding list, with public comments open through June 29, 2026. If finalized, this could affect the availability, pricing, and continuity of some compounded GLP-1 programs. We will update this page as the regulatory situation develops.
Variation 1: Formal
Regulatory Update — May 2026
The FDA has proposed excluding semaglutide and liraglutide from the 503B bulk compounding list. Public comments are open through June 29, 2026. If the proposal is finalized, it may affect the availability, pricing, or operational structure of some compounded GLP-1 medication programs. RangeYourself will continue monitoring the issue and update this page as the regulatory landscape develops.
Best for: Provider review pages, GLP-1 Price Index methodology pages, formal comparison pages.
Variation 2: Conversational
Regulatory Update — May 2026
Compounded GLP-1 access may change. The FDA has proposed excluding semaglutide and liraglutide from the 503B bulk compounding list, with public comments open through June 29, 2026. That does not mean compounded GLP-1 programs disappear overnight, but it could affect availability, pricing, and how some providers operate. We will update this page as more information becomes available.
Best for: Consumer-facing buying guides.
Variation 3: Brief
Regulatory Update — May 2026
The FDA has proposed excluding semaglutide and liraglutide from the 503B bulk compounding list. Public comments are open through June 29, 2026. If finalized, the proposal could affect compounded GLP-1 availability and pricing.
Best for: Short callout boxes, pricing tables, provider comparison blurbs.
Placement Guidance
- Near the first mention of compounded GLP-1 medications (high-intent pages)
- Directly below the first pricing table (comparison pages)
- Inside or after the "Compounded vs Brand-Name" section (educational pages)
- In the GLP-1 Price Index methodology or update log (transparency)
Styling
- Yellow/light amber callout box
- Border: soft amber or gold
- Text: dark brown or charcoal
- Visually distinct from affiliate disclosures
- Do NOT use red unless urgent safety update
Pages That Should Receive the Note
- GLP-1 Price Index
- Best GLP-1 Weight Loss Programs 2026
- Cheapest GLP-1 Programs Online
- Compounded vs Brand-Name GLP-1 explainer
- ShedRx, TMates, Sprout Health, Direct Meds reviews
- Wegovy Pill comparison
- Any state page mentioning compounded pricing
Language Rules
Use "proposed" and "if finalized." Never say FDA has already banned compounded GLP-1s.
RangeYourself is reader-supported. We may earn a commission when you click on certain links — at no extra cost to you. Editorial recommendations are made independently. Last reviewed May 7, 2026.
